Lung Transplantation as Therapeutic Option in Acute Respiratory Distress Syndrome for Coronavirus Disease 2019-Related Pulmonary Fibrosis
The outbreak of coronavirus disease 2019 (COVID-19) has posed unprecedented challenges to global healthcare systems. Among the most severe complications of COVID-19 is acute respiratory distress syndrome (ARDS), which can lead to irreversible pulmonary fibrosis and fatal respiratory failure. Despite maximal medical support, including mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO), some patients progress to end-stage lung disease. Lung transplantation (LT) has emerged as a potential salvage therapy for these critically ill patients. This article provides a comprehensive overview of the use of LT in COVID-19-related pulmonary fibrosis, based on a case series of three patients who underwent the procedure in China.
Introduction
COVID-19, caused by the novel coronavirus SARS-CoV-2, has resulted in millions of infections and hundreds of thousands of deaths worldwide. A significant proportion of patients with severe COVID-19 develop ARDS, characterized by rapid onset of respiratory failure, pulmonary inflammation, and fibrosis. While most patients recover with supportive care, some progress to irreversible lung damage, despite negative virological test results. In these cases, LT has been considered as a last-resort treatment to save lives.
Methods
Ethical Approval and Patient Selection
The study was conducted in accordance with ethical guidelines, and approval was obtained from the institutional ethics committees of the Shenzhen Third People’s Hospital and the Wuxi People’s Hospital. Three male patients with COVID-19-related ARDS and irreversible pulmonary fibrosis were urgently assessed and listed for LT. All patients had been on MV and ECMO for extended periods, with no signs of lung function recovery. Consecutive negative nucleic acid tests from multiple sites confirmed their virological status as positive-turned-negative. The patients’ families provided informed consent for the procedures.
Preoperative Assessment and Logistics
The patients, aged 58 to 73 years, had comorbidities such as hypertension, diabetes, and chronic kidney disease. Preoperative chest imaging revealed extensive pulmonary consolidation and fibrotic changes (Figure 1). All patients had extremely high Sequential Organ Failure Assessment (SOFA) scores and elevated D-dimer levels, indicating severe organ dysfunction and coagulopathy. The LT procedures were performed in specialized negative-pressure operating rooms with the highest level of protection for the medical team (Table 3). The logistics included intercity transportation of patients and the establishment of green channels for organ procurement and allocation.
Surgical Procedure and Perioperative Management
Bilateral LT was the primary choice for all patients. Patient 1, who had unstable hemodynamics, was considered for combined heart and lung transplantation. The surgeries were performed under ECMO support, with central cannulated veno-arterial (VA)-ECMO established intraoperatively to manage pulmonary hypertension and cardiac dysfunction. The right lung was explanted first in all cases, followed by the left lung. The explanted lungs showed severe consolidation, edema, and intra-pulmonary hematoma (Figure 2E).
Patient 1 developed ventricular fibrillation during the left lung transplant, necessitating emergent heart transplantation. Despite initial recovery, the patient succumbed to uncontrolled bleeding and cardiac arrest. Patients 2 and 3 underwent successful bilateral LT, with intraoperative management of recurrent atrial fibrillation in Patient 3. Both patients were weaned off intraoperative VA-ECMO and maintained on low-dose inotropes postoperatively.
Postoperative Care and Rehabilitation
Patients 2 and 3 regained consciousness on postoperative day (POD) 1 and were weaned off ECMO 37 and 40 hours after LT, respectively. Cyclosporine A was administered at a lower-than-conventional dose, and antiviral, antibiotic, and antifungal therapies were initiated. Early rehabilitation programs, including respiratory and physical therapy, were started on POD 2 and 3. Both patients progressed to standing balance training and intermittent weaning off MV by POD 12 and 22 (Figure 2F). Bronchoscopy and chest tube removal were performed without complications.
Pathological Findings
The explanted lungs from Patients 1 and 2 showed extensive hemorrhage, fibrosis, and thrombosis, consistent with end-stage ARDS (Table 2). These findings provided insights into the severe pulmonary injury caused by COVID-19 and highlighted the irreversible nature of the disease in these patients.
Discussion
Timing and Indications for LT
LT in COVID-19 patients with ARDS and pulmonary fibrosis represents a novel therapeutic approach. The decision to proceed with LT was based on confirmed irreversibility of respiratory failure, positive-turned-negative virological status, and absence of contraindications. The use of ECMO as a bridge to LT was critical in stabilizing patients before surgery. The high SOFA scores in these patients indicated a significant risk of mortality, making LT a life-saving option.
Challenges and Best Practices
The LT procedures were performed under strict infection control measures to protect the medical team. Specialized head covers with positive pressure were used to prevent contamination, and intraoperative rotation plans were implemented to manage physical exhaustion. Remote video communication tools facilitated coordination between the surgical team and external experts. The success of the procedures relied on meticulous planning, teamwork, and adherence to safety protocols.
Long-Term Outcomes and Immune Considerations
The long-term outcomes of LT in COVID-19 patients remain to be fully understood. The presence of positive IgG antibodies in Patients 2 and 3 suggested potential immunity, but close monitoring for viral relapse is essential. The use of immunosuppressive regimens post-LT requires careful consideration to balance the risk of rejection and infection. Further research is needed to evaluate the immune status and cytokine profiles of these patients.
Conclusion
LT can be a viable therapeutic option for end-stage COVID-19 patients with ARDS and pulmonary fibrosis. The success of the procedures in this case series underscores the importance of timely intervention, meticulous planning, and comprehensive perioperative management. The collaboration between medical teams, public health systems, and regulatory authorities played a pivotal role in achieving positive outcomes. As the global pandemic continues, LT may offer a lifeline for critically ill patients with no other treatment options.
doi.org/10.1097/CM9.0000000000000839
Was this helpful?
0 / 0